

FDA clears BD Phoenix CPO test

March 2019—BD announced that its BD Phoenix CPO detect test to identify infections caused by carbapenemase-producing organisms has received 510(k) clearance by the Food and Drug Administration. The phenotypic test, available in two configurations as part of the BD Phoenix automated microbiology system, detects CPOs and, depending on configuration, can provide the Ambler classification of the enzyme produced. The test is included on BD Phoenix Gram-negative panels and can detect CPOs accurately in less than 36 hours.

[BD](#), 201-847-6800